Understand the source comparison
TB-4 Research Menstrual Cycle Considerations: Comparison
Follicular (days 2–10) 20–100 pg/mL <1 ng/mL Low, rising TB-4-driven VEGF upregulation operates against low baseline. Greatest fold-change potential Ideal phase for capturing TB-4's maximal VEGF effect without hormonal amplification Late Follicular / Ovulation
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Follicular (days 2–10)
- 20–100 pg/mL
- <1 ng/mL
- Low, rising
- TB-4-driven VEGF upregulation operates against low baseline. Greatest fold-change potential
- Ideal phase for capturing TB-4's maximal VEGF effect without hormonal amplification
- Late Follicular / Ovulation (days 11–14)
- 200–400 pg/mL
- Peak
- Estrogen independently maximizes VEGF and EPC mobilization. TB-4 effect additive but difficult to isolate
- Strongest observed outcomes but reduced ability to attribute effect solely to TB-4
- Early Luteal (days 15–21)
- 100–200 pg/mL
- 5–15 ng/mL
- Moderate, declining
- Progesterone begins suppressing inflammatory pathways TB-4 would modulate
- Transition phase. Results highly variable depending on exact progesterone timing
- Mid-Late Luteal (days 22–28)
- 50–150 pg/mL
- 10–20 ng/mL
- Low
- Progesterone-dominant environment suppresses cytokine targets and MMP activity
- Least responsive phase for TB-4 anti-inflammatory and ECM remodeling endpoints
- Menses (days 1–5)
- <50 pg/mL
- Elevated (prostaglandin-driven)
- Increased vascular permeability accelerates tissue penetration but also clearance
- Pharmacokinetic profile differs significantly. Faster distribution, shorter half-life